Comparative Efficacy and Safety of Nimesulide Versus Piroxicam in Osteoarthritis with Special Reference to Chondroprotection

Sharma, Sangeeta; Rastogi, Shipra; Gupta, Vijay; Rohtagi, D.; Gulati, Pratima

doi:10.1097/00045391-199907000-00003

Cited by 15 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Extra outcome data were provided for only eight of these studies. [37][38][39][40][41][42][43][44] Five offered data on outcomes not previously recorded for that study, five offered information that no events had occurred in some outcomes and four offered data differing from those already collected from the study publication(s). Replies about the same eight studies and one further study 45 provided extra information on study quality (method of randomisation, allocation concealment, etc.…”

Section: Contact With Trialistsmentioning

confidence: 99%

“…107,116,122 Authors of five studies provided additional information on outcomes when contacted. 37,38,40,42,44 Participants Thirty-eight studies included only adults with OA and nine studies included only adults with RA. Two studies included participants with 'degenerative joint disease', one study included participants with both OA and RA and one study only recruited participants with AS.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

“…In five trials the authors explicitly reported that only the participants and the healthcare providers had been blinded to treatment. 38,40,42,44,119 A priori sample size calculations were performed in 14 studies and not mentioned in the remainder. Fifteen studies analysed their primary outcome data using the ITT principle.…”

Section: Study Qualitymentioning

confidence: 99%

See 2 more Smart Citations

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

show abstract

Section: Contact With Trialistsmentioning

confidence: 99%

Section: Characteristics Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

show abstract

“…В отличие от индо-метацина, значительно повреждающего хрящ, нимесулид in vitro даже в высоких дозах не нарушал синтез протеогликана хрящевой тканью [28,29].…”

Section: гу институт ревматологии рамн москваunclassified

Use of nimesulide in rheumatology

Il'ina¹,

Кудаева²,

Ilyina³

et al. 2008

Modern Rheumatology Journal

View full text Add to dashboard Cite

“…Piroxicam is a nonsteroidal anti-inflammatory drug used to treat arthritis and other inflammatory conditions (1). Crystalline piroxicam is polymorphic and exists in various crystalline forms designated as form I, form II, form III, and monohydrate form.…”

Section: Introductionmentioning

confidence: 99%

Use of Drifts and PLS for the Determination of Polymorphs of Piroxicam Alone and in Combination with Pharmaceutical Excipients: A Technical Note

2008

View full text Add to dashboard Cite

Comparative Efficacy and Safety of Nimesulide Versus Piroxicam in Osteoarthritis with Special Reference to Chondroprotection

Cited by 15 publications

References 0 publications

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Use of nimesulide in rheumatology

Use of Drifts and PLS for the Determination of Polymorphs of Piroxicam Alone and in Combination with Pharmaceutical Excipients: A Technical Note

Contact Info

Product

Resources

About